Farzad Haerizadeh, M.Sc., Ph.D.

Farzad has more than 20 years of experience in life sciences and biotech industries with a strong focus on cellular therapy and immuno-oncology drug development including CAR-T, allogeneic CAR-T, allogeneic ‘off the shelf’ stem cell/iPSC-based therapeutics.

Dr. Haerizadeh is Chief Scientific Officer at Bio4t2, and EVP of Bridgewest Group, he brings extensive experience to BioViros as scientific advisor and expert in genomics, mammalian cell engineering and genome editing and synthetic biology.

Farzad held multiple senior leadership R&D roles in several pharma and biotech companies such as F1 Oncology (now Exuma Biotech) as the VP of R&D, Intrexon Corporation (now Precigen, Inc), Synthetic Genomics Inc, Life Technologies Corporation (now ThermoFisher Scientific) and Codexis Inc., where he initiated and directed multiple cutting-edge adaptive cell therapy (engineering T cells, T cell receptors (TCRs), NK cells) and therapeutics discovery platforms, xenotransplantation, protein engineering and industrial enzymes evolution programs. Among these, four cell therapy drugs are currently in different stages of clinical trials. Farzad is also experienced in bio-manufacturing and product development.

Farzad holds a PhD and a postdoctoral fellowship in Molecular, Cellular & Systems Biology from the University of Melbourne, Australia, and a postdoctoral fellowship Biophysics from Stanford University, California.